Compare Inovio Pharmaceuticals Inc (INO) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Smith & Nephew plc — how do they compare? Inovio Pharmaceuticals Inc trades at $1.12 (market cap $112.19M), while Smith & Nephew plc trades at $27.22 (market cap $11.10B). The key difference: Smith & Nephew plc is far larger — about 98.9× Inovio Pharmaceuticals Inc's market cap, and Smith & Nephew plc pays a 2.95% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Inovio Pharmaceuticals Inc for 43 Days and Smith & Nephew plc for 121 Days on average.
| INO | SNN | |
|---|---|---|
Market Cap | $112.19M | $11.10B |
Volume | 3,201,278 | 1,051,703 |
Sector | Health | Health |
52-Week High | $2.65 | $37.17 |
52-Week Low | $0.66 | $26.42 |
Typical Hold Time | 43 Days | 121 Days |
Enterprise Value | $83.51M | $14.13B |
Dividend Yield | — | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Inovio Pharmaceuticals (INO) trades at $1.09, down 5.63% today, reflecting ongoing financial challenges with minimal revenue of $65,340 in 2025 and substantial losses. The company shows consistent negative cash flow from operations but has beaten EPS estimates in recent quarters. Technical indicators are bearish, with moving averages and oscillators signaling selling pressure. Key near-term catalyst is the FDA's October 30, 2026 PDUFA date for INO-3107, its lead candidate for recurrent respiratory papillomatosis.
The investment case hinges on FDA approval of INO-3107, with analyst consensus target at $2.75 offering significant upside. However, high burn rate, negative margins, and dependence on financing pose substantial risks. Positive regulatory outcome could drive revaluation, but failure may exacerbate financial strain. Wall Street maintains cautious optimism with 59% buy ratings.
SNN trades at $27.10, near its 52-week low, with a bearish technical signal. The company reported solid fundamentals with revenue growth to $6.16B in 2025 and a net income margin of 10.08%. Recent product launches, like the EVOS PELVIC System, aim to strengthen its medical technology portfolio. Cash flow from operations remains strong at $1.29B, though net cash flow was negative $64M in 2025.
The outlook is mixed: strong profitability and innovation support long-term value, but near-term headwinds include analyst downgrades and competitive pressures. Risks involve execution challenges and market sentiment. The stock presents a cautious opportunity for value investors, balancing solid fundamentals against current bearish trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
